Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084105 | 0.88 | TRPV1 (0.60) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14084097 | 0.88 | TRPV1 (0.65) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14083687 | 0.87 | KCNQ3 (0.49) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14083082 | 0.87 | TRPV1 (0.57) | TRPV1HDAC4SCN5ASCN9A | |
| SCHEMBL14084120 | 0.87 | KCNQ3 (0.70) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14084089 | 0.86 | TRPV1 (0.66) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14084072 | 0.85 | TRPV1 (0.70) | TRPV1HDAC4 | |
| SCHEMBL14084125 | 0.84 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL14084106 | 0.84 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14253406 | 0.84 | TRPV1 (0.58) | TRPV1KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885KCNQ3 87/4885KCNQ2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.